Search results
Showing 31 to 45 of 1300 results for heart OR cardi* OR arrythmia
This indicator covers the percentage of patients with a diagnosis of heart failure on or after 1 April 2026 who have a recorded ejection fraction category (reduced, mildly reduced, or preserved). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over with heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM238
ENDURALIFE powered CRT-D devices for treating heart failure (HTG433)
Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.
Heart failure: mortality within 12 months of admission (IND8)
This indicator covers all-cause mortality within 12 months following a first emergency admission to hospital for heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG11
This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.
NICE is unable to make a recommendation on vericiguat (Verquvo) for treating chronic heart failure with reduced ejection fraction in adults because Bayer did not provide an evidence submission.
Show all sections
Sections for TA731
Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.
View recommendations for HTG757Show all sections
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
This indicator covers admission rates due to heart failure in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG61
This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.
This webpage covers all NICE's guidelines on cardiometabolic disease prevention and treatment The table presents the guidelines...
Cardiac contractility modulation device implantation for heart failure (IPG655)
Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults. This involves placing a device under the skin of the chest, which delivers electrical pulses to make the heart contract more strongly.
View recommendations for IPG655Show all sections
Evidence-based recommendations on artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure. This involves replacing the 2 lower chambers of the heart with a mechanical device to improve circulation until heart transplantation.
View recommendations for IPG602Show all sections
This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.
The OPTIMIZER smart system for managing heart failure (MIB186)
NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .